



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003826 F 12/05/1988 34 Y

Referral Testing

Collected: 09/07/2023 08:42 Received: 09/07/2023 08:42

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: ZAP-70, BLOOD, H, <10, %, QCRL. Row 2: ZAP70+/CD19+, 74, H, <10, %, QCRL.

93% of the lymphocytes are CD19 positive and 69% of the selected lymphocytes express ZAP70 with CD19. Therefore, 74% of the B-cells (CD19 positive) are ZAP70 positive.

Our data shows that patients with >= 10% ZAP70 positive cells have more aggressive disease.

Positivity for ZAP-70 in the leukemic cells in patients with chronic lymphocytic leukemia usually, but not always, correlates with more aggressive disease, unmutated IgVH, and positivity for CD38. Negativity for ZAP-70 does not always rule out unmutated IgVH or aggressive disease. We strongly recommend correlation with IgVH mutation.

As an internal control, we gated on T-cells. 6% of the lymphocytes are CD3 positive and 4% of the selected lymphocytes express ZAP70 with CD3. Therefore, 67% of the T-cells (CD3 positive) are ZAP70 positive.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Test Performed at:
Quest Diagnostics Nichols Institute
33608 Ortega Highway
San Juan Capistrano, CA 92675-2042 I Maramica MD, PhD, MBA

Table with 6 columns: Viability, 96, H, %, QCRL.

QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA 92675

Reported Date: 2023.09.07 8:43 ZAP70

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F307000005 Ordered By: KAJAL SITWALA, MD, PhD
WX0000003826 WX00000000002353
Printed D&T: 09/07/23 08:43

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1
PAGE 1 OF 1